Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Shares Outstanding (Diluted Average): 2020-2024

Historic Shares Outstanding (Diluted Average) for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Dec 2024 value amounting to $121.0 million.

  • Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) rose 6.90% to $132.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $132.9 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $121.0 million for FY2024, which is 74.53% up from last year.
  • As of FY2024, Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) stood at $121.0 million, which was up 74.53% from $69.3 million recorded in FY2023.
  • Arcutis Biotherapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $121.0 million during FY2024, with a 5-year trough of $35.7 million in FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Diluted Average) was $69.3 million (2023), whereas its average is $81.8 million.
  • Data for Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 74.53% (in 2024) over the last 5 years.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' Shares Outstanding (Diluted Average) stood at $35.7 million in 2020, then surged by 38.51% to $49.4 million in 2021, then climbed by 11.39% to $55.0 million in 2022, then climbed by 25.94% to $69.3 million in 2023, then soared by 74.53% to $121.0 million in 2024.